A study to confirm the effect of Tacrolimus eye drops in patients with corneal neovascularization

A Prospective, Multicenter Comparative Case-Control Study to investigate the Clinical Efficacy of 0.1% Tacrolimus in Patients with Corneal Neovascularization

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0006770

Enrollment

Registered

2021-11-19

Start date

2022-01-03

Completion date

Unknown

Last updated

2021-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Experimental and control groups are determined according to the randomization table prepared in advance for the study subjects (random number generation using Excel program). For the experiment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who visited Asan Medical Center, Yonsei University Severance Hospital, and Korea University Ansan Hospital, were diagnosed with corneal neovascularization and voluntarily agreed to participate in the clinical trial. 2) Corneal neovascularization is diagnosed based on the following criteria. i. When blood vessels and opacities are observed from the limbus to the center of the cornea

Exclusion criteria

Exclusion criteria: 1) In case of active ocular surface inflammatory disease 2) Those who have used Cyclosporine, steroids, or systemic immunosuppression (Glucocorticoids, Cyclophosphamide, Azathioprine, Methotrexate, etc.) within 2 weeks of the test period 3) History of ophthalmic surgery and trauma within the last 3 months. - However, if LASEK/LASIK has been operated within 12 months, it is not possible to participate in the clinical trial. 4) Those who are planning ophthalmic surgery (including LASIK/LASIK) during the study period 5) Pregnant women, lactating women, and female patients planning to become pregnant 6) Patients with hypersensitivity to investigational drugs 7) Patients who are allergic to fluorescein or eye drops 8) Contact lens wearers 9) Others judged inappropriate by the investigator

Design outcomes

Primary

Measure	Time frame
Corneal neovascularization grade	—

Secondary

Measure	Time frame
Ocular surface staining grade (Oxford and Sicca Staining);Eye Symptoms Questionnair;Visual acuity;Intraocular pressure;Anterior segment optical coherence tomography ;Anterior segment photo ;Specular microscopy	—

Countries

Korea, Republic of

Contacts

Public ContactYoungsub Eom

Korea University Ansan Hospital

hippotate@hanmail.net+82-31-412-5168

Outcome results